Madam Chair, I will turn the question over to Dr. Stewart, who I think is best placed to speak to the drug approval process in this particular case of generic OxyContin. If there is an opportunity after he responds to provide some data that we're aware of in the way of uptake of the generic OxyContin versions as well as the new version of OxyContin, I'd be happy to add that, but I want to ensure he has time to answer that part of the question. Thank you.
On November 6th, 2013. See this statement in context.